By Lee Greenberger, Ph.D., LLS Chief Scientific Officer | January 11, 2023 The most important blood cancer scientific meeting, the American Society of Hematology (ASH), is held every December. This meeting, followed closely by the start of the new year, is the perfect time to reflect on progress in patient…

By Brianna Wilson, Senior Manager, Advocacy Communications | August 17, 2022 Today, cancer patients — and others with other chronic conditions — are breathing a collective sigh of relief. …

By Brianna Wilson, Senior Manager, Advocacy Communications | October 3, 2022 — LLS and blood cancer advocates are celebrating after our efforts helped make two bills become law in California, advancing health equity and improving cancer care for thousands. Charlie’s Law After seeing firsthand how difficult it could be for non-White patients to find a match for bone marrow transplants, LLS advocate…

By Lee Greenberger, PhD, Chief Scientific Officer at LLS | May 26, 2022 The Food and Drug Administration (FDA) recently approved azacitidine (Vidaza®) for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML). JMML is an uncommon blood cancer that accounts for 1–2% of all childhood…

By Ryan Holeywell | April 13, 2022 New York’s newly-signed budget contains a key reform that could be nothing short of lifesaving for some cancer patients living in the state. The new budget, signed by Gov. Kathy Hochul Saturday, will make National Cancer Institute-designated cancer centers “in-network” for over 5…

By Lee Greenberger, PhD, Chief Scientific Officer at LLS | April 5, 2022 The U.S. Food and Drug Administration (FDA) last week approved axicabtagene ciloleucel (axi-cel, Yescarta®) for patients with large B-cell lymphoma (LBCL) who either did not respond to first-line standard chemotherapy or relapsed within 12 months. Until now, CAR T-therapies like axi-cel have been saved for blood cancer patients who have…

By Lee Greenberger, PhD, Chief Scientific Officer at LLS | March 1, 2022 Ciltacabtagene Autoleucel (cilta-cel) is the second CAR-T approved to treat multiple myeloma Just one year after the first CAR T-cell treatment was approved for multiple myeloma, the second is about to hit the market. The FDA approved…

By Lee Greenberger, Ph.D., LLS Chief Scientific Officer The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. …

The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Roughly half of all ALL cases occur in adults, and unlike pediatric ALL, adults have historically had…